Statins ineffective for dementia

Compared with placebo, there was no benefit from statins seen with the primary outcome measure, Alzheimer's Disease Assessment Scale – cognitive subscale (ADAS-Cog) or the Mini Mental State Examination. There was no significant difference in behaviour, global function or activities of daily living in the statin and placebo groups. All participants had a diagnosis of probable or possible Alzheimer’s disease (AD) according to standard criteria and most participants were established on cholinesterase inhibitors. Participants’ ages ranged from 50 to 90 years, and treatment was given for at least 6 months. There were no significant differences in adverse effects between treatment and placebo groups